Early Insights Case Study Webinar Series
Welcome to our Early Insights webinar series where key experts in medical retina, from both the UK and the US, discuss their patient cases and experience treating neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO) with EYLEA® (aflibercept) 8 mg.
Meet our expert speakers for this webinar series:
Professor of Ophthalmology at York University and Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust
Consultant Ophthalmologist at University Hospitals Bristol and Weston NHS Foundation Trust
Chairman of Ophthalmology at Mayo Clinic, US
MD, Vitreoretinal Surgeon at Retina Associates of Kentucky, USA
Early Insights Case Study Webinar 2
Treating nAMD and DMO patients in clinical practice
Join Richard Gale, Serena Salvatore and John Kitchens in this recording of our second EYLEA 8 mg Early Insights webinar. Tune in as they share their patient cases and experience treating neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO) with EYLEA 8 mg in their practices in both the UK and US.
Prescribing information for EYLEA® (aflibercept) can be found here.
Early Insights Case Study Webinar 1
Initiating nAMD and DMO patients in clinical practice
Join our expert panelists as they share and compare clinical experiences of commencing patients and treating neovascular age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO) with case studies from both the US and the UK.
In this webinar session, Professor Richard Gale presents case studies from his clinic, providing insight into commencing eligible nAMD and DMO patients with EYLEA 8 mg. Professor Gale discusses his experience injecting the higher dose and initial treatment responses in relation to vision, fluid and safety profile.
Prescribing information for EYLEA® (aflibercept) can be found here.
PP-EYL-GB-2577 | November 2024